NASDAQ:VRNA

Verona Pharma Stock Forecast, Price & News

$8.20

-0.02 (-0.24 %)

(As of 04/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$8.06

Now: $8.20▼

$8.69

50-Day Range

$7.51

MA: $8.64▼

$9.30

52-Week Range

$3.70

Now: $8.20▼

$15.71

Volume43,115 shs

Average Volume127,376 shs

Market Capitalization$475.07 million

P/E RatioN/A

Dividend YieldN/A

Beta0.4

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRNA

Previous Symbol

CUSIPN/A

CIK1657312

Webwww.veronapharma.com

Phone44-20-3283-4200

Employees25

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.04

Current Ratio2.99

Quick Ratio2.99

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.28 per share

Price / Book2.50

Profitability

EPS (Most Recent Fiscal Year)($3.10)

Net Income$-40,780,000.00

Net MarginsN/A

Return on Equity-115.93%

Return on Assets-73.68%

Miscellaneous

Outstanding Shares57,935,000

Market Cap$475.07 million

Next Earnings Date4/29/2021 (Estimated)

OptionableNot Optionable

Headlines

-$0.45 EPS Expected for Verona Pharma plc (NASDAQ:VRNA) This Quarter
April 7, 2021 | americanbankingnews.com

Verona Pharma Target of Unusually High Options Trading (NASDAQ:VRNA)
March 30, 2021 | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) Sees Significant Increase in Short Interest
March 29, 2021 | americanbankingnews.com

Revisiting Verona Pharmaceuticals
March 2, 2021 | seekingalpha.com

Verona Pharma plc 2020 Q4 - Results - Earnings Call Presentation
February 26, 2021 | seekingalpha.com

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
February 18, 2021 | markets.businessinsider.com

Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
February 2, 2021 | msn.com

CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
February 2, 2021 | finance.yahoo.com

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
January 14, 2021 | finance.yahoo.com

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 5, 2021 | finance.yahoo.com

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 5, 2021 | feeds.benzinga.com

News for Verona Pharma PLC Registered Shs
December 24, 2020 | markets.businessinsider.com

Is VRNA A Good Stock To Buy Now?
December 11, 2020 | finance.yahoo.com

25 Best U.S. Cities to Live With Asthma
November 25, 2020 | finance.yahoo.com

Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
November 23, 2020 | finance.yahoo.com

Verona Pharma EPS beats by $0.15
October 30, 2020 | seekingalpha.com

Verona Pharma Plcto Host Earnings Call
October 29, 2020 | finance.yahoo.com

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
October 29, 2020 | finance.yahoo.com

Verona COPD Trial, And Other News: The Good, Bad And Ugly Of Biopharma
October 27, 2020 | seekingalpha.com

Verona Pharma plc (I9S1.SG)
October 11, 2020 | in.finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.69 out of 5 stars

Medical Sector

282nd out of 2,019 stocks

Pharmaceutical Preparations Industry

122nd out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Verona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Verona Pharma has a forecasted upside of 131.7% from its current price of $8.20.
Amount of Analyst Coverage
Verona Pharma has received no research coverage in the past 90 days.

3.5 Community Rank

Outperform Votes
Verona Pharma has received 279 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Verona Pharma has received 122 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Verona Pharma has received 69.58% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote “Outperform” if you believe VRNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Verona Pharma does not currently pay a dividend.
Dividend Growth
Verona Pharma does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,629.00 in company stock.
Percentage Held by Institutions
54.51% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Verona Pharma are expected to grow in the coming year, from ($1.36) to ($1.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verona Pharma is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verona Pharma is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verona Pharma has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$8.20

-0.02 (-0.24 %)

(As of 04/14/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions

Is Verona Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Verona Pharma stock.
View analyst ratings for Verona Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Verona Pharma?

Wall Street analysts have given Verona Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verona Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verona Pharma?

Verona Pharma saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 98,100 shares, an increase of 104.8% from the February 28th total of 47,900 shares. Based on an average daily volume of 126,100 shares, the days-to-cover ratio is presently 0.8 days.
View Verona Pharma's Short Interest.

When is Verona Pharma's next earnings date?

Verona Pharma is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Verona Pharma.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings data on Thursday, February, 25th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.19.
View Verona Pharma's earnings history.

How has Verona Pharma's stock price been impacted by Coronavirus?

Verona Pharma's stock was trading at $4.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VRNA shares have increased by 69.4% and is now trading at $8.20.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VRNA?

3 brokers have issued 1-year target prices for Verona Pharma's stock. Their forecasts range from $17.00 to $23.00. On average, they expect Verona Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 131.7% from the stock's current price.
View analysts' price targets for Verona Pharma or view top-rated stocks among Wall Street analysts.

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the following people:

Dr. David S. Zaccardelli, Pres, CEO & Exec. Director (Age 56, Pay $701.63k)
Mr. Mark W. Hahn, Chief Financial Officer (Age 58, Pay $560.07k)
Dr. Kathleen A. Rickard, Chief Medical Officer (Age 63, Pay $722.76k)
Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 54)
Ms. Victoria Stewart, Director of Communications
Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 59)
Ms. Nina Church, Exec. Director of Global Clinical Devel.
Mr. Benjamin Harber, Company Sec.
Mr. Christopher Martin, VP of Commercial

Who are some of Verona Pharma's key competitors?

Some companies that are related to Verona Pharma include Seres Therapeutics (MCRB), MacroGenics (MGNX), Morphic (MORF), Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), FibroGen (FGEN), CytoDyn (CYDY), Amneal Pharmaceuticals (AMRX), Cytokinetics (CYTK), Prelude Therapeutics (PRLD), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY) and Aurinia Pharmaceuticals (AUPH).
View all of VRNA's competitors.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

How do I buy shares of Verona Pharma?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $8.20.

How much money does Verona Pharma make?

Verona Pharma has a market capitalization of $475.07 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does Verona Pharma have?

Verona Pharma employs 25 workers across the globe.

What is Verona Pharma's official website?

The official website for Verona Pharma is www.veronapharma.com.

Where are Verona Pharma's headquarters?

Verona Pharma is headquartered at 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]

This page was last updated on 4/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here